LUTREPULSE KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUTREPULSE KIT is a small-molecule injectable indicated for reproductive endocrinology conditions, approved in 1989. The product mechanism of action and specific indications are not publicly detailed in available data. It represents a mature, established therapeutic intervention in the fertility and hormone management space.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating defensive strategy and potential team contraction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LUTREPULSE KIT offers limited career growth due to LOE approaching status and zero linked job openings. Roles available are primarily defensive, focused on margin protection and managed decline rather than expansion.
Brand ManagerRegional Sales Manager
Worked on LUTREPULSE KIT at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.